A Phase IIa Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effects of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With Alendronate

Trial Profile

A Phase IIa Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effects of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With Alendronate

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2017

At a glance

  • Drugs Odanacatib (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 06 Mar 2017 The primary endpoint has been amended to include the safety endpoints as well - Participants Experiencing One or More Adverse Events and Participants Discontinuing Study Drug Due to an AE
    • 15 Jun 2013 Results presented at the 14th Annual Congress of the European League Against Rheumatism.
    • 08 Mar 2013 Planned number of patients changed from 244 to 247 as reported by Clinical Trials Registry - India.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top